ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > ErbB4

ErbB4

概要

Name:Receptor protein-tyrosine kinase erbB-4
Target Synonym:EC 2.7.10,EC:2.7.10.1,ERBB4,Tyrosine kinase-type cell surface receptor HER4,s80HER4,p180erbB4,Receptor tyrosine-protein kinase erbB-4,4ICD,E4ICD,HER4,Erb-B2 Receptor Tyrosine Kinase 4,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 4,Human Epidermal Growth Factor Receptor 4,Proto-Oncogene-Like Protein C-ErbB-4,V-Erb-A Avian Erythroblastic Leukemia Viral Oncogene Homolog-Like 4,Avian Erythroblastic Leukemia Viral (V-Erb-B2) Oncogene Homolog 4,V-Erb-A Erythroblastic Leukemia Viral On
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
ER4-H5251 Human Human ErbB4 / Her4 Protein, Fc Tag
ER4-H5251-structure
ER4-H5251-sds
ER4-H5221 Human Human ErbB4 / Her4 Protein, His Tag
ER4-H5221-structure
ER4-H5221-sds
ACRO Quality

生物活性データの一部

ER4-H5221-ELISA
 ErbB4 ELISA

Immobilized Human ErbB4, His Tag (Cat. No. ER4-H5221) at 2 μg/mL (100 μL/well) can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.5-8 ng/mL (QC tested).

ER4-H5251-ELISA
 ErbB4 ELISA

Immobilized Human ErbB4, Fc Tag (Cat. No. ER4-H5251) at 2 μg/mL (100 μL/well) can bind Human NRG1-beta 1 Protein with a linear range of 0.6-10 ng/mL (Routinely tested).

Synonym Name

HER4,ErbB4,MGC138404,p180erbB4

Background

Receptor tyrosine-protein kinase erbB-4 (ErbB4), also known as Her4, is a single-pass type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain and several breast carcinomas. ERBB4 contains multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer. ERBB4 has been shown to interact with: DLG4, NRG1, STAT5A, and YAP1. Mutations in this gene have been associated with cancer. Other single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Dacomitinib PF-299; PF-804; PF-299804; PF-00299804; PF-00299804-3; PF-00299804-03 Approved Pfizer Inc Vizimpro Mainland China Carcinoma, Non-Small-Cell Lung Pfizer Europe Ma Eeig 2018-09-27 Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Penile Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Head and Neck Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Liver Diseases; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours Details
Afatinib Dimaleate BIBW-2992; BIBW-2992-MA2 Approved C.H. Boehringer Sohn Ag & Co. Kg Gilotrif, Tomtovok, 吉泰瑞, Tovok, Giotrif Mainland China Carcinoma, Non-Small-Cell Lung Boehringer Ingelheim International Gmbh 2013-07-12 Lymphoma; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Ureteral Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Breast Neoplasms; Uterine Neoplasms; Glioma; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Hematologic Neoplasms; Liver Diseases; Urinary Bladder Neoplasms; Chordoma; Multiple Myeloma; Neuroectodermal Tumors; Glioblastoma; Neoplasms; Neoplasms, Squamous Cell; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Rhabdomyosarcoma; Head and Neck Neoplasms; Solid tumours Details
Osimertinib Mesylate AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 Approved Astrazeneca Pharmaceutical Co Ltd 泰瑞沙, Tagrisso Mainland China Carcinoma, Non-Small-Cell Lung Astrazeneca Ab 2015-11-13 Uterine Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Cholangiocarcinoma; Lymphoma; Glioma; Endometrial Neoplasms; Thyroid Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma of Lung; Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Colonic Neoplasms; Glioblastoma; Multiple Myeloma; Urinary Bladder Neoplasms Details
Pyrotinib Maleate HTI-1001; SHR-1258; BLTN Approved Jiangsu Hengrui Medicine Co Ltd 艾瑞妮 Mainland China Breast Neoplasms Jiangsu Hengrui Medicine Co Ltd 2018-08-12 Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
Neratinib Maleate CAN-030; HKI-272; PF-0528767; WAY-179272; PB-272 Approved Pfizer Pharmaceuticals Ltd (China) Nerlynx, 贺俪安 Mainland China Breast Neoplasms Excella Gmbh & Co Kg 2017-07-17 Solid tumours; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
JRF-103 JRF103; JRF-103 Phase 2 Clinical Shenzhen Jinrui Foundation Biotechnology Co Ltd Solid tumours Details
PB-357 PB-357 Phase 1 Clinical Pfizer Inc Neoplasms Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
JK-07 JK-07 Shenzhen Salubris Pharmaceuticals Co Ltd Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
XZP-5209 XZP-5209 Phase 1 Clinical Carcinoma, Non-Small-Cell Lung Details
Tarloxotinib Bromide PR-610; TH-4000; SN-33999 Phase 2 Clinical Threshold Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Tesevatinib XL-647; KD-020; KD-019; EXEL-7647 Phase 2 Clinical Exelixis Inc Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Larotinib Mesylate Z-650 Phase 3 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma Details
FCN-411 FCN-411 Phase 2 Clinical Shanghai Fosun Pharmaceutical (Group) Co Ltd Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pirotinib Hydrochloride KBP-5209 Phase 2 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totopphone